Published in New England Journal of Medicine · View the paper (DOI)
A phase 1/2 trial of CRISPR gene editing has demonstrated safety and efficacy, with measurable improvements in 11 out of 14 participants with a form of inherited blindness. The treatment, EDIT-101, was found to be clinically meaningful for four participants and showed significant improvements in cone-mediated vision.
Coverage from 2 institutions
- CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows Mass Eye and Ear · May 6, 2024 · first to report
- Participants of pioneering CRISPR gene editing trial see vision improve Oregon Health & Science University · May 6, 2024